Mar 10, 2022 / NTS GMT
Ludvig Svensson -
(foreign language) Erik Penser Bank's Bolagsdag. Now (foreign language) Klaus Sindahl for Hansa Biopharma. So (foreign language).
Klaus Sindahl - Hansa Biopharma AB(publ)-Head of IR
Yes. (foreign language) I hope it's okay I'll do the presentation in English, even though you can ask questions to me afterwards in Swedish. I'm happy to answer those. But thank you so much for inviting me to this Erik Penser Bolagsdag. I'm very much looking forward to present Hansa for you.
Before I start, I just need to show you this forward-looking statement. So you, of course, need to discount whatever I say.
Yes, Hansa Biopharma, for those who are new to the case, I just want you to understand where we are today. It's a fully commercial-stage biopharmaceutical company based out of Lund. We are roughly 130 employees today. Actually, it's a good organization now, I mean, commercial-stage, et cetera. So we are now building our team across R&D and commercial. And it's a very experienced team. I mean we have, on average,
Hansa Biopharma AB Erik Penser Bolagsdag Stockholm Transcript
Mar 10, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers